WVU Medicine Berkeley Medical Center and Jefferson Medical Center are now offering a leading-edge treatment for non-hospitalized, high-risk patients with a mild or moderate case of COVID-19.
Monoclonal antibodies are laboratory-made antibodies that mimic the immune system’s ability to fight off harmful viruses. The treatments offered at Berkeley and Jefferson Medical Centers are specifically designed to help block the COVID-19 virus and prevent the virus from further infecting healthy cells.
The Food and Drug Administration has granted emergency use authorization to several monoclonal antibody treatments for COVID-19. Administered intravenously, this innovative treatment is designed to help lessen the severity of COVID-19 in individuals who are COVID-19 positive and are at risk for developing a severe form of the disease.
There is specific criteria patients must meet in order to receive the monoclonal antibody treatment. To qualify, you must:Have a lab-confirmed case of COVID-19
- Be older than 12 years of age
- Have an onset of symptoms less than seven days
- Be high risk because of certain underlying chronic health conditions
- Be stable enough to not require hospitalization
About the Treatment
Treatment involves a one-time dose through an IV infusion which takes approximately one hour to administer. During this time, the patient is monitored for any adverse reaction. Patients are then monitored for one hour post procedure in the clinic before going home.
If you think you may be eligible for this treatment, please contact your health care provider directly for more information.